|
|
|
Stem Cell Related Patent Number US5328695
| Title: | Muscle morphogenic protein and use thereof | | Inventors: | Lucas, Paul A.; Macon, GA, USA
Young, Henry E.; Macon, GA, USA
Laurenchin, Cato T.; Somerville, MA, USA | | Summary: | This invention introduces a muscle morphogenic protein and properties by which it stimulates lineage commitment and the differentiation of stem cells both in vitro and in vivo. Described herein is a myogenic protein isolate from mammalian bone which is characterized by its ability to cause muscle stem cell differentiation without excessive proliferation of connective tissue proximal to the delivery site. Further described are methods by which treated muscle stem cells have been shown to differentiate into myotubes and multinucleated structures with minimal formation of scar tissue, resulting in functional muscle tissue restoration in vivo. Also provided are techniques by which the protein isolate may be administered by implanting a bioerodible polymer matrix, preferably a surface erodible polymer such as a polyanhydride or a polyorthoester, interspersed with the protein isolate near the site of muscle injury or degeneration, or alternately administered directly to cells cultured in vitro. Therapeutic applications are included for the treatment of a wide range of muscular injuries and disorders, included but not limited to muscular dystrophy, myasthenia gravis and multiple sclerosis. | | Abstract: | A myogenic protein isolate from mammalian bone is provided that stimulates lineage commitment and differentiation of stem cells in vitro and in vivo. The protein isolate is characterized by its ability to cause muscle stem cell differentiation without excessive proliferation of connective tissue proximal to the delivery site. Treated muscle stem cells differentiate into myotubes and multinucleated structures with minimal formation of scar tissue, resulting in functional muscle tissue restoration in vivo, and therefore useful in the treatment of a number of disorders and injuries. The protein isolate is preferably administered by implanting a bioerodible polymer matrix, preferably a surface erodible polymer such as a polyanhydride or a polyorthoester, interspersed with the protein isolate near the site of muscle injury or degeneration, but can be administered directly to cells cultured in vitro. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US5328695 | | Application Number: | US1992000835727 | | Date Filed: | 11/02/1992 | | Date Published: | 12/07/1994 | | Assignee: | Massachusetts Institute of Technology, Cambridge, MA, USA |
|
|
